{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T13:53:05Z","timestamp":1774014785169,"version":"3.50.1"},"reference-count":15,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.cmi.2023.03.021","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T03:43:11Z","timestamp":1679456591000},"page":"826-828","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Which trial do we need? A global, adaptive, platform trial to reduce death and disability from tuberculous meningitis"],"prefix":"10.1016","volume":"29","author":[{"given":"Guy E.","family":"Thwaites","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Watson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nguyen Thuy","family":"Thuong Thuong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Walker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nguyen Hoan","family":"Phu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2023.03.021_bib1","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nrneurol.2017.120","article-title":"Tuberculous meningitis international research consortium. Tuberculous meningitis","volume":"13","author":"Wilkinson","year":"2017","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.cmi.2023.03.021_bib2","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S1474-4422(21)00435-X","article-title":"Tuberculous meningitis: progress and remaining questions","volume":"21","author":"Huynh","year":"2022","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.cmi.2023.03.021_bib3","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1056\/NEJMoa1507062","article-title":"Intensified antituberculosis therapy in adults with tuberculous meningitis","volume":"374","author":"Heemskerk","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2023.03.021_bib4","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1128\/AAC.00064-11","article-title":"Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis","volume":"55","author":"Thwaites","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2023.03.021_bib5","doi-asserted-by":"crossref","first-page":"292","DOI":"10.12688\/wellcomeopenres.16474.1","article-title":"Tuberculous meningitis international research consortium. Host directed\u00a0therapies for tuberculous meningitis","volume":"5","author":"Davis","year":"2020","journal-title":"Wellcome Open Res"},{"key":"10.1016\/j.cmi.2023.03.021_bib6","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1056\/NEJMoa040573","article-title":"Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults","volume":"351","author":"Thwaites","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2023.03.021_bib7","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2023.03.021_bib8","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","article-title":"AIDS clinical trials group; tuberculosis trials consortium. Four-Month rifapentine regimens with or without moxifloxacin for tuberculosis","volume":"384","author":"Dorman","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2023.03.021_bib9","doi-asserted-by":"crossref","first-page":"886","DOI":"10.5588\/ijtld.21.0515","article-title":"UNITE4TB: a new consortium for clinical drug and regimen development for TB","volume":"25","author":"Boeree","year":"2021","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.cmi.2023.03.021_bib10","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1016\/S1473-3099(18)30110-5","article-title":"Tuberculosis: progress and advances in the development of new drugs, treatment\u00a0regimens,\u00a0and host-directed therapies","volume":"18","author":"Tiberi","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2023.03.021_bib11","doi-asserted-by":"crossref","first-page":"7974","DOI":"10.1038\/s41467-022-35730-3","article-title":"Dynamic 18F-pretomanid PET imaging in animal models of TB meningitis and human studies","volume":"13","author":"Mota","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.cmi.2023.03.021_bib12","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/cid\/ciw757","article-title":"Tuberculous Meningitis International Research Consortium. Standardized methods for enhanced quality and comparability of tuberculous meningitis studies","volume":"64","author":"Marais","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2023.03.021_bib13","doi-asserted-by":"crossref","first-page":"158","DOI":"10.12688\/wellcomeopenres.15501.2","article-title":"Tuberculous Meningitis International Research Consortium. Management of intracranial tuberculous mass lesions: how long should we treat for?","volume":"4","author":"Marais","year":"2019","journal-title":"Wellcome Open Res"},{"key":"10.1016\/j.cmi.2023.03.021_bib14","doi-asserted-by":"crossref","first-page":"ofaa604","DOI":"10.1093\/ofid\/ofaa604","article-title":"Use of infliximab to treat paradoxical tuberculous meningitis reactions","volume":"8","author":"Marais","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2023.03.021_bib15","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.medj.2022.07.001","article-title":"Interleukin-1 receptor antagonist anakinra as treatment for paradoxical responses in HIV-negative tuberculosis patients: a case series","volume":"3","author":"van Arkel","year":"2022","journal-title":"Med"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X23001386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X23001386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:33:14Z","timestamp":1761118394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X23001386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1198743X23001386"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2023.03.021","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Which trial do we need? A global, adaptive, platform trial to reduce death and disability from tuberculous meningitis","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2023.03.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}